It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval
The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
The order strengthens the company’s position in the East African market
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The focus is on wellness and personal care products
Subscribe To Our Newsletter & Stay Updated
